Phase 2 Lung Cancer Trial, Recruiting (NCT07038096)

Phase 2 Lung Cancer Trial, Recruiting NCT07038096 Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07038096 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who fully understand the study and are willing to sign a consent form agreeing to take part.
People aged between 18 and 70 years old (male or female).
People who have been diagnosed with advanced small cell lung cancer or a related cancer type called neuroendocrine carcinoma, confirmed through a tissue or cell sample test.
People who are generally able to care for themselves and carry out light activity — rated 0 or 1 on a standard scale doctors use to measure how well a person is functioning day-to-day (confirm with trial site).
People who are expected to live for more than 3 months.

Who may not be able to join:

People whom the trial doctor considers unsuitable for the study for any other medical or personal reason not listed above (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jason Wu, Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phone: +86-0512-57309965

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07038096

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase: Phase 2

Status: Recruiting

Condition: Lung Cancer

Trial contact: +86-0512-57309965

More information: https://clinicaltrials.gov/study/NCT07038096

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who fully understand the study and are willing to sign a consent form agreeing to take part.
People aged between 18 and 70 years old (male or female).
People who have been diagnosed with advanced small cell lung cancer or a related cancer type called neuroendocrine carcinoma, confirmed through a tissue or cell sample test.
People who are generally able to care for themselves and carry out light activity — rated 0 or 1 on a standard scale doctors use to measure how well a person is functioning day-to-day (confirm with trial site).
People who are expected to live for more than 3 months.

Who may not be able to join:

People whom the trial doctor considers unsuitable for the study for any other medical or personal reason not listed above (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Registry

ClinicalTrials.gov

Start date

23 September 2025

Est. completion

1 September 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of Participants Who Experienced Dose-limiting Toxicity (DLT); Number of Participants With Treatment-emergent Adverse Events (TEAEs); Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov